StockNews.com started coverage on shares of Arcadia Biosciences (NASDAQ:RKDA – Free Report) in a research report report published on Thursday. The brokerage issued a sell rating on the basic materials company’s stock.
Several other analysts have also issued reports on the stock. Lake Street Capital upgraded shares of Arcadia Biosciences to a strong-buy rating in a research report on Tuesday, May 14th. HC Wainwright reissued a buy rating and set a $10.00 price objective on shares of Arcadia Biosciences in a research report on Friday, April 5th.
Get Our Latest Analysis on RKDA
Arcadia Biosciences Price Performance
Arcadia Biosciences (NASDAQ:RKDA – Get Free Report) last posted its earnings results on Thursday, May 9th. The basic materials company reported ($1.78) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.52) by $0.74. The company had revenue of $1.26 million for the quarter, compared to the consensus estimate of $1.20 million. Arcadia Biosciences had a negative return on equity of 84.27% and a negative net margin of 129.74%. During the same quarter in the prior year, the company earned ($3.83) earnings per share. Equities research analysts anticipate that Arcadia Biosciences will post -5.01 EPS for the current year.
About Arcadia Biosciences
Arcadia Biosciences, Inc produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief, and SoulSpring.
Further Reading
- Five stocks we like better than Arcadia Biosciences
- How to Calculate Options Profits
- MarketBeat Week in Review – 5/20 – 5/24
- 3 Tickers Leading a Meme Stock Revival
- NASDAQ 100 vs. NASDAQ Composite: A Detailed Breakdown of NASDAQ
- Trading Stocks: RSI and Why it’s Useful
- These 2 Retail Traders Favorites are Nearing Major Breakouts
Receive News & Ratings for Arcadia Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcadia Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.